WO1998046563A1 - Metalloproteinase inhibitors - Google Patents
Metalloproteinase inhibitors Download PDFInfo
- Publication number
- WO1998046563A1 WO1998046563A1 PCT/GB1998/000958 GB9800958W WO9846563A1 WO 1998046563 A1 WO1998046563 A1 WO 1998046563A1 GB 9800958 W GB9800958 W GB 9800958W WO 9846563 A1 WO9846563 A1 WO 9846563A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- ethyl
- compound
- phenyl
- Prior art date
Links
- FKFBJWJJPJMYQX-UHFFFAOYSA-N NC(C(CS)NC(c(cc1)ccc1-c1ccccc1)=O)=O Chemical compound NC(C(CS)NC(c(cc1)ccc1-c1ccccc1)=O)=O FKFBJWJJPJMYQX-UHFFFAOYSA-N 0.000 description 1
- CIPIXWGWRYSYIM-UHFFFAOYSA-N NC(C(CS)NS(c(cc1)ccc1-c1ccccc1)(=O)=O)=O Chemical compound NC(C(CS)NS(c(cc1)ccc1-c1ccccc1)(=O)=O)=O CIPIXWGWRYSYIM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to therapeutically active N-acyl alpha amino acid amides having a mercapto or acyl mercapto group in the amino acid side chain, to processes for their preparation, to pharmaceutical compositions containing them, and to the use of such compounds in medicine.
- the compounds are inhibitors of metalloproteinases involved in tissue degradation.
- MMPs matrix metalloproteinases
- the matrix metalloproteinases are a family of enzymes including interstitial collagenase, neutrophil collagenase, collagenase-3, 72kDa gelatinase, 92kDa gelatinase, stromelysin-1 , stromelysin-2, stromelysin-3, matrilysin, macrophage metalloelastase, membrane-type metalloproteinase-1 and membrane-type metalloproteinase-2. These enzymes share a common zinc-containing catalytic domain and a pro-sequence which maintains latency.
- MMPs can express MMPs in response to activation by inflammatory stimuli such as interleukin-1 or tumour necrosis factor- ⁇ (TNF- ⁇ ).
- inflammatory stimuli such as interleukin-1 or tumour necrosis factor- ⁇ (TNF- ⁇ ).
- TNF- ⁇ tumour necrosis factor- ⁇
- Different stimuli can induce overlapping yet distinct repertoires of MMPs and different cell types can respond to the same stimuli by expression of distinct combinations of MMPs.
- MMPs can attack the protein components of extracellular matrix such as collagens, vitronectin and elastin, and have recently been shown to process membrane proteins such as pro-TNF- ⁇ to release soluble TNF- ⁇ .
- MMPs are thought to play a central role in the pathology of inflammatory diseases such as rheumatoid arthritis as well as in the growth and metastasis of tumours.
- Compounds which have the property of inhibiting the action of MMPs are thought to be potentially useful for the treatment or prophylaxis of conditions involving such tissue breakdown, for example rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, and tumour metastasis, invasion and growth.
- MMP inhibitors are also of potential value in the treatment of neuroinflammatory disorders, including those involving myelin degradation, for example multiple sclerosis, as well as in the management of angiogenesis dependent diseases, which include arthritic conditions and solid tumour growth as well as psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumours, angiofibromas and hemangiomas.
- MMP inhibitors Two known classes of pseudopeptide or peptide mimetic MMP inhibitors have a hydroxamic acid group or a carboxylic group respectively as their zinc binding groups. Many such known MMPs may be represented by the structural formula (IA)
- X is the zinc binding hydroxamic acid (-CONHOH) or carboxylic acid (- COOH) group and the groups P ⁇ to R 5 are variable in accordance with the specific prior art disclosures of such compounds.
- WO 96/16027 discloses a class of MMP inhibitor compounds which can be represented by formula (IA) above.
- the principal structural characterising feature of the compounds disclosed in WO 96/16027 is the group R 2 which is defined in the publication as being a group R 2 -X- wherein X is -(CH 2 ) m -Y- (CH 2 ) n , Y being O, S or a single bond, m and n being 0, 1 , 2, 3 or 4 and m+n being 0, 1 , 2, 3, or 4, and R 2 being (inter alia) aryl or heteroaryl, the latter terms including biaryl such as biphenyl and heteroaryl-aryl such as 4-pyridylphenyl.
- R ⁇ R 2 and the N-containing ring are variable in accordance with the specific disclosures of the publications.
- MMP inhibitors which are C-terminal amido-, N-terminal acyl- dipeptides, wherein the zinc binding group is a mercapto group located in the side chain of the N-terminal amino acid.
- the present invention makes available a class of compounds which differ in structure from those disclosed by Foley et. al. principally in that they are derivatives of a single amino acid rather than a dipeptide, but also in other respects, for example the identity of the N-acyl group. Despite these structural modification relative to Foley et. al., compounds of the invention have been found to retain MMP inhibitory activity.
- n is O or l ;
- A represents an optionally substituted phenyl or heteroaryl group
- B represents a divalent 1 ,4-phenylene moiety or a divalent C C 4 alkylene or C 2 - C 4 alkenylene or C 2 -C 4 alkynylene moeity;
- R 3 represents:
- R x and R y each independently represents an optionally substituted phenyl or heteroaryl group which may be linked covalently to each other by a bond or by a divalent C r C 4 alkyl or C 2 -C 4 alkenyl bridge, or (ii) R x represents a group D-(C 1 -C 6 alkyl)- wherein D is as defined above in relation to R and R 2 , or is an optionally substituted phenyl or heteroaryl, group, and R y represents an optionally substituted phenyl or heteroaryl ring;
- R 3 and R 4 taken together represent a divalent chain of formula -C(R a )(R b )- A 1 -Alk- wherein R a and R b are independently hydrogen or C C 6 alkyl, A 1 is a bond, -0-, -S-, -S-S-, -NH- or -NR a - wherein R a is C r C 6 alkyl, and Alk is a divalent C r C 4 alkylene moeity;
- R 4 represents hydrogen or a C C 6 alkyl group
- R 5 represents hydrogen or acyl
- R 6 represents hydrogen, a C C 6 alkyl group, or a group D-(C 1 -C 6 alkyl)- wherein wherein D is as defined above in relation to R ⁇ and R 2 ;
- cycloalkyl means a saturated alicyclic moiety having from 3-8 carbon atoms and includes, for example, cyclohexyl, cyclooctyl, cycloheptyl, cyclopentyl, cyclobutyl and cyclopropyl.
- cycloalkenyl means an unsaturated alicyclic moiety having from 4-8 carbon atoms and includes, for example, cyclohexenyl, cyclooctenyl, cycloheptenyl, cyclopentenyl, and cyclobutenyl. In the case of cycloalkenyl rings of from 5-8 carbon atoms, the ring may contain more than one double bond.
- acyl means a group R 20 C(O)- where R 20 is C r C 6 alkyl, C 2 -C 6 alkenyl, cycloalkyl, phenyl, heterocyclyl, pheny C ⁇ C ⁇ alkyl, heterocyclyl(C C 6 )alkyl, cycloalkyl(C r C 6 alkyl), phenyl(C 2 -C 6 alkenyl), heterocyclyl(C 2 -C 6 alkenyl), cycloalkyl(C 2 -C 6 alkenyl), any of which R 20 groups may be substituted.
- heterocyclyl or “heterocyclic” as used herein means a 5-7 membered aromatic or non-aromatic heterocyclic ring containing one or more heteroatoms selected from S, N and O, and optionally fused to a carbocyclic or second heterocyclic ring.
- Specific examples of such groups include pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, and benzimidazolyl.
- heteroaryl as used herein means an aromatic 5 or 6 membered monocyclic aromatic heterocyclic group. Specific examples of the latter include thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, trizolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl.
- An “optionally substituted phenyl or heteroaryl group” is a phenyl or heteroaryl group which is either unsubstituted or is substituted, and the term “substituted” means substituted with 1 , 2, 3 or 4 compatible substituents selected from C r C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C r C 8 alkoxy, C 1 -C 6 alkoxy(C r C 6 alkoxy), hydroxy, mercapto, C C 8 alkylthio, C C 6 alkylthioC r C 6 alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, nitro, CN, -COOH, -CONH 2 , -COOR A , -NHCOR A , -NHC0 2 R A , -CONHR A , or -CONR A R B where
- protected when used in relation to an amino, hydroxy, mercapto, or carboxy group means a derivative of such a group which is substantially nonfunctional.
- Such groups are widely known, for example from the art of peptide synthesis, and are discussed in the widely used handbook by T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2nd Edition, Wiley, New York, 1991.
- amides for example as a NHCOC ⁇ C g alkyl amide
- carbamates for example as an N
- Salts of the compounds of the invention include physiologically acceptable acid addition salts for example hydrochlorides, hydrobromides, sulphates, methane sulphonates, p-toluenesulphonates, phosphates, acetates, citrates, succinates, lactates, tartrates, fumarates and maleates. Salts may also be formed with bases, for example sodium, potassium, magnesium, and calcium salts.
- the group A in the compounds of the invention represents an optionally substituted phenyl or heteroaryl group.
- Heteroaryl A groups may be bonded to the rest of the molecule (I) via a ring carbon atom in A or via a ring nitrogen atom in A.
- the substituent is preferably in the 4-position of the ring relative to the bond connecting A to the rest of molecule (I).
- membered A groups such as phenyl and pyridyl
- the substituent is preferably in the 3- or 4-position of the ring relative to the bond connecting A to the rest of molecule (I).
- a sole substituent in A may be any of those defined above for "substituted”.
- substituents include C r C 6 alkyl eg methyl, ethyl, n-propyl, n-butyl, n-pentyl and n-hexyl; trifluoromethyl; halo eg chloro; cyano ( -CN); -OH; and -OR, wherein R is C,-C 6 alkyl, C r C 6 alkoxy(C r C 6 alkyl), or benzyl.
- n may be 0 or 1 ;
- Group A may, for example, be phenyl, 4-chlorophenyl, 4-ethylphenyl, 4-n- hexylphenyl, 4-n-octyloxyphenyi; or pyridin-4-yl;
- Groups R 1 and R 2 may independently be, for example, hydrogen; a C r C 6 alkyl group for example methyl, ethyl, n- or iso-propyl, n-, sec- or tert-butyl, n- pentyl or n-hexyl; or a group D-(CH 2 ) m -, wherein m is 1-6, for example 1 , 2, 3 or 4, and D is, for example maleimido, succinimido, phthalimido, 1 ,2-dimethyl- 3,5-dioxo-1 ,2,4-triazolidin-4-yl, 3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl, 2- methyl-3,5-dioxo-1 ,2,4-oxadiazol-4-yl, 3-methyl-2,4,5-trioxo-1-imidazolidinyl, 2,5-dioxo-3-phenyl-1 -imi
- groups R., and R 2 may form, for example, a cycloalkyl or cycloalkenyl ring, for example a cyclopropyl, cyclobutyl cyclopentyl, cyclohexyl, cyclohex-1 ,2-enyl, cyclohex- 2,3-enyl, or cyclohex-3,4-enyl ring;
- Group R 3 may for example be
- R 3 groups of this type include phenyl, 2-methoxyphenyl, 3- methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 2- fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3- chiorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-iodophenyl, 3- iodophenyl, 4-iodophenyl, 2-methylphenyl, 3-methylphenyl, 4- methylphenyl, 3,4-dimethyl, 2-t-butylphenyl, 3-t-butylphenyl, 4-t-butyl-2,6-dimethylphenyl, 2-nitrophenyl, 3-nitrophenyl
- R x and R y independently represent optionally substituted phenyl, thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinolyl, pyrimidinyl, piperazinyl or triazinyl.
- R x and R y include phenyl, 4-chlorophenyl and pyridinyl. Where R x and R y are linked covalently, an example of a group R 4 is 9- H-fluoren-9-yl;
- a polyether chain possessing at least two non-adjacent oxygen atoms for example 2-(2-methoxyethoxymethoxy)ethyl, 1 ,1-dimethyl-2-(2- methoxyethoxymethoxy)ethyl , 2-(2-ethoxyethoxymethoxy)ethyl , 2-(2- (2-methoxyethoxy)ethoxy)ethyl, 2-(2-(3-methoxypropoxymethoxy)ethyl, 3-(2-methoxyethoxymethoxy)propyl, 2,2-dimethyl-3-(2- methoxyethoxymethoxy)propyl, 2-(2-methoxyethoxy)ethyl, 3-(2- methoxyethoxy)-propyl, 2-methyl-2,2-di(2-methoxyethyl)propyl, 2- methyl-2,2-di(2-methoxyethyl)butyl, and 2-methyl-2,2-di(2- methoxy
- Groups R 3 and R 4 taken together may, for example, be -(CH 2 )-0-(CH 2 ) 2 -, -(CH 2 ) 5 -, -C(CH 3 ) 2 SCH 2 CH 2 CH 2 -, or -C(CH 3 ) 2 SSCH 2 CH 2 -.
- Group R 4 may for example be hydrogen, methyl or ethyl
- Group R 5 may for example be hydrogen, or a group R 20 C(O)- where R 20 is methyl or ethyl;
- Group R 6 may for example be hydrogen, methyl, ethyl, n- or iso-propyl, n-, sec- or tert-butyl, or a group D-(CH 2 ) m - as exemplified above for R ⁇ and R 2 .
- A, B X, n, R ⁇ R 2 , R 3 , R 4 , and R 6 are as defined in general formula (I) except that any substituents in A, R 3 , and R 4 , which are potentially reactive in the condensation reaction may themselves be protected from such reaction, and Z represents a mercapto protecting group, and subsequently removing the protecting group Z and any protecting groups present in A, R 3 , and R 4 .
- Active derivatives of acids (II) include activated esters such as the hydroxybenzotriazolyl, hydroxysuccinyl or pentafluorophenyl ester, acid anhydrides and acid halides, eg chlorides.
- Suitable mercapto protecting groups may be selected from those known in the art and include trityl.
- n, Z, R ⁇ R 2 , and R 6 are as defined in general formula (I), and Z, represents a protected amino group, and subsequently removing the protecting group Z and the protecting group(s) present in Z.
- the protected amino group Z may be an amino group covalently linked to a solid state support such as an amino functionalised resin as used in solid phase peptide synthesis.
- a solid state support such as an amino functionalised resin as used in solid phase peptide synthesis.
- the free amino compound of the invention is cleaved from the resin by photolysis or acid hydrolysis in the usual way.
- R 5 is acyl
- R 5 is hydrogen
- R 5 is hydrogen
- this invention concerns:
- a method of management by which is meant treatment or prophylaxis of diseases or conditions mediated by MMPs in mammals, in particular in humans, which method comprises administering to the mammal an effective amount of a compound as defined with respect to formula (I) above, or a pharmaceutically acceptable salt thereof;
- Diseases or conditions mediated by MMPs include those involving tissue breakdown, angiogenesis, and inflammation, in particular rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, wound healing, psoriasis, tumour invasion by secondary metastases, tumour growth, proliferative retinopathy, neovascular glaucoma, ocular tumours, angiofibromas and hemangiomas as well as neuroinflammatory disorders, including those involving myelin degradation, for example multiple sclerosis.
- a pharmaceutical or veterinary composition comprising a compound of formula (I) together with a pharmaceutically or veterinarily acceptable excipient or carrier.
- One or more compounds of general formula (I) may be present in the composition together with one or more excipient or carrier.
- the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy. Optimum dose levels and frequency of dosing will be determined by clinical trial.
- the compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties.
- the orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions.
- Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example magnesium stearate, talc, polyethylene glycoi or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate.
- the tablets may be coated according to methods well known in normal pharmaceutical practice.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycoi, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
- suspending agents for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats
- emulsifying agents for example lecithin, sorbitan monooleate, or acacia
- non-aqueous vehicles which may include edible oils
- almond oil fractionated coconut oil
- oily esters such as glycerine, propylene
- the drug may be made up into a cream, lotion or ointment.
- Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
- the drug may be made up into a solution or suspension in a suitable sterile aqueous or non aqueous vehicle.
- Additives for instance buffers such as sodium metabisulphite os disodium edeate; preservatives including bactericidal and fungicidal agents such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorhexidine, and thickening agents such as hypromellose may also be included.
- the active ingredient may also be administered parenterally in a sterile medium.
- the drug can either be suspended or dissolved in the vehicle.
- adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
- the resin was then drained, washed with DMF (2 x 10 ml), dichloromethane (DCM) 3 x 15 ml, methanol (2 x 10 ml), DCM ( 2x 10 ml) and then dried in vacuo.
- the resin gave a negative Kaiser test.
- a 20% solution of piperidine in DMF (5 ml) was added to the resin. After 5 min this was drained from the resin and replaced with a further 5 ml of piperidine solution and the resin gently agitated for 25 minutes before the solution was drained and the resin washed thoroughly with DMF (5 x 10 ml).
- a resin bead gave a positive Kaiser test.
- the desired compound was liberated from the resin by treatment for 2 h with a solution (4 ml) of a TFA solution containing anisole (0.2 ml), ethanedithiol (0.3 ml), thioanisole (0.45 ml), water (0.2 ml) and triisopropylsilane (0.15 ml) made upto 10 ml.
- the TFA solution was then filtered into a collection tube, the resin washed with a further 2 ml of TFA and the combined filtrates evaporated to leave a solid gum. Trituration with cold diethylether (10 ml) caused the desired product to precipitate.
- Fmoc-S-trityl-L-cysteine (5.30 g, 9.04 mmol) and HOBt (1.46 g) were dissolved in DMF (60 ml) and cooled in an ice bath.
- WSCDI (2.08 g, 10.86 mmol) was added and the solution was stirred for 2 h at 0°C when a solution of methylamine in ethanol (2.25 ml of a 33% solution (8.03M)) was added.
- Example 11 Biphenyl-4-carboxylic acid (1 R-dimethylcarbamoyl-2-mercaptoethyl)-amide
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54358698A JP2001519826A (en) | 1997-04-11 | 1998-03-31 | Metalloproteinase inhibitor |
US09/402,666 US6258851B1 (en) | 1997-04-11 | 1998-03-31 | Metalloproteinase inhibitors |
EP98913950A EP0971887A1 (en) | 1997-04-11 | 1998-03-31 | Metalloproteinase inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9707333.2 | 1997-04-11 | ||
GBGB9707333.2A GB9707333D0 (en) | 1997-04-11 | 1997-04-11 | Metalloproteinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998046563A1 true WO1998046563A1 (en) | 1998-10-22 |
Family
ID=10810625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/000958 WO1998046563A1 (en) | 1997-04-11 | 1998-03-31 | Metalloproteinase inhibitors |
Country Status (5)
Country | Link |
---|---|
US (1) | US6258851B1 (en) |
EP (1) | EP0971887A1 (en) |
JP (1) | JP2001519826A (en) |
GB (1) | GB9707333D0 (en) |
WO (1) | WO1998046563A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0930067A2 (en) * | 1997-12-19 | 1999-07-21 | Pfizer Products Inc. | Mmp inhibitors for the treatment of ocular angiogenesis |
US6420427B1 (en) | 1997-10-09 | 2002-07-16 | Ono Pharmaceutical Co., Ltd. | Aminobutyric acid derivatives |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE457716T1 (en) | 2002-12-30 | 2010-03-15 | Angiotech Int Ag | RELEASE OF ACTIVE INGREDIENTS FROM QUICK-GELLING POLYMER COMPOSITION |
US7945590B2 (en) * | 2005-01-06 | 2011-05-17 | Microsoft Corporation | Programmability for binding data |
US7953696B2 (en) * | 2005-09-09 | 2011-05-31 | Microsoft Corporation | Real-time synchronization of XML data between applications |
KR101679568B1 (en) | 2014-10-02 | 2016-11-28 | 한국과학기술연구원 | Alpha-aminoamide derivatives and pharmaceutical composition comprising the same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52142036A (en) * | 1976-05-21 | 1977-11-26 | Taiho Pharmaceutical Co Ltd | Production of thiol |
WO1994025434A1 (en) * | 1993-04-27 | 1994-11-10 | Celltech Limited | Peptidyl derivatives as metalloproteinase inhibitors |
WO1995019961A1 (en) * | 1994-01-22 | 1995-07-27 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
WO1996016027A1 (en) * | 1994-11-22 | 1996-05-30 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
WO1996016931A1 (en) * | 1994-11-26 | 1996-06-06 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
-
1997
- 1997-04-11 GB GBGB9707333.2A patent/GB9707333D0/en active Pending
-
1998
- 1998-03-31 EP EP98913950A patent/EP0971887A1/en not_active Withdrawn
- 1998-03-31 JP JP54358698A patent/JP2001519826A/en active Pending
- 1998-03-31 US US09/402,666 patent/US6258851B1/en not_active Expired - Fee Related
- 1998-03-31 WO PCT/GB1998/000958 patent/WO1998046563A1/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52142036A (en) * | 1976-05-21 | 1977-11-26 | Taiho Pharmaceutical Co Ltd | Production of thiol |
WO1994025434A1 (en) * | 1993-04-27 | 1994-11-10 | Celltech Limited | Peptidyl derivatives as metalloproteinase inhibitors |
WO1995019961A1 (en) * | 1994-01-22 | 1995-07-27 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
WO1996016027A1 (en) * | 1994-11-22 | 1996-05-30 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
WO1996016931A1 (en) * | 1994-11-26 | 1996-06-06 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Section Ch Week 7802, Derwent World Patents Index; Class B05, AN 78-03403A, XP002069825 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6420427B1 (en) | 1997-10-09 | 2002-07-16 | Ono Pharmaceutical Co., Ltd. | Aminobutyric acid derivatives |
EP0930067A2 (en) * | 1997-12-19 | 1999-07-21 | Pfizer Products Inc. | Mmp inhibitors for the treatment of ocular angiogenesis |
EP0930067A3 (en) * | 1997-12-19 | 1999-09-15 | Pfizer Products Inc. | MMP inhibitors for the treatment of ocular angiogenesis |
Also Published As
Publication number | Publication date |
---|---|
JP2001519826A (en) | 2001-10-23 |
US6258851B1 (en) | 2001-07-10 |
EP0971887A1 (en) | 2000-01-19 |
GB9707333D0 (en) | 1997-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU695507B2 (en) | Metalloproteinase inhibitors | |
US6207698B1 (en) | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same | |
KR100418808B1 (en) | Metalloproteinase inhibitors | |
US6271262B1 (en) | Metalloproteinase inhibitors | |
EP0873304B1 (en) | Metalloproteinase inhibitors | |
US6242467B1 (en) | Compounds | |
US20080227833A1 (en) | Oxa- and thiadiazoles and their use as metalloproteinase inhibitors | |
WO1995009841A1 (en) | Hydroxamic acid derivatives as inhibitors of cytokine production | |
OA10764A (en) | Protease inhibitors | |
SK174899A3 (en) | Urokinase inhibitors | |
CA2371876A1 (en) | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | |
EP0865339B1 (en) | Metalloproteinase inhibitors | |
MX2007007433A (en) | Novel cyclohexane derivatives. | |
US6239151B1 (en) | Compounds as inhibitor of tumor necrosis factor alpha release | |
JP2002537294A (en) | Di- and tripeptide nitrile derivatives as inhibitors of cathepsin L and cathepsin S | |
WO1997003783A9 (en) | Metalloproteinase inhibitors | |
CA2448418A1 (en) | Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors | |
US6258851B1 (en) | Metalloproteinase inhibitors | |
WO1998023588A9 (en) | Metalloproteinase inhibitors | |
US7504537B2 (en) | Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient | |
AU4973500A (en) | Alpha-amino-beta-sulfonyl hydroxamic acid compounds | |
EP0944587B1 (en) | Metalloproteinase inhibitors | |
GB2315750A (en) | Metalloproteinase inhibitors | |
AU2259100A (en) | Protease inhibitors - I | |
AU2260500A (en) | Protease inhibitors - III |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998913950 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 543586 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09402666 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998913950 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998913950 Country of ref document: EP |